NBC Securities Inc. Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

NBC Securities Inc. cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.8% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 160 shares of the biopharmaceutical company’s stock after selling 42 shares during the quarter. NBC Securities Inc.’s holdings in Regeneron Pharmaceuticals were worth $168,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Park Avenue Securities LLC lifted its stake in shares of Regeneron Pharmaceuticals by 9.2% during the 1st quarter. Park Avenue Securities LLC now owns 1,671 shares of the biopharmaceutical company’s stock worth $1,609,000 after purchasing an additional 141 shares during the period. International Assets Investment Management LLC lifted its position in Regeneron Pharmaceuticals by 9.4% during the first quarter. International Assets Investment Management LLC now owns 736 shares of the biopharmaceutical company’s stock worth $713,000 after buying an additional 63 shares during the period. Ballentine Partners LLC boosted its stake in Regeneron Pharmaceuticals by 37.7% in the 1st quarter. Ballentine Partners LLC now owns 1,040 shares of the biopharmaceutical company’s stock worth $1,001,000 after buying an additional 285 shares during the last quarter. Northwest Investment Counselors LLC purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $177,000. Finally, Traynor Capital Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 4.7% during the 1st quarter. Traynor Capital Management Inc. now owns 19,746 shares of the biopharmaceutical company’s stock valued at $19,005,000 after acquiring an additional 878 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $990.68 on Friday. The firm has a market cap of $109.16 billion, a price-to-earnings ratio of 29.27, a PEG ratio of 3.45 and a beta of 0.12. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The business’s 50 day moving average is $1,109.58 and its two-hundred day moving average is $1,040.38. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the company posted $8.79 earnings per share. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.85 EPS for the current fiscal year.

Analysts Set New Price Targets

REGN has been the topic of several research analyst reports. Barclays raised their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Morgan Stanley lowered their price objective on shares of Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Royal Bank of Canada increased their target price on Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. Canaccord Genuity Group reissued a “buy” rating and set a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. Finally, TD Cowen raised their price objective on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,116.00.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.